| Item Type | Name |
|
Concept
|
Treatment Outcome
|
|
Academic Article
|
Angiotensin converting enzyme inhibitors and calcium antagonists alone or combined: does the progression of diabetic renal disease differ?
|
|
Academic Article
|
Antihypertensive efficacy of candesartan in comparison to losartan: the CLAIM study.
|
|
Academic Article
|
Choices and goals in the treatment of the diabetic hypertensive patient.
|
|
Academic Article
|
Design and statistical aspects of the African American Study of Kidney Disease and Hypertension (AASK).
|
|
Academic Article
|
Roundtable discussion: problems in the management of hypertension.
|
|
Academic Article
|
Comparison of telmisartan vs. valsartan in the treatment of mild to moderate hypertension using ambulatory blood pressure monitoring.
|
|
Academic Article
|
Achieving goal blood pressure in patients with type 2 diabetes: conventional versus fixed-dose combination approaches.
|
|
Academic Article
|
Orlistat improves blood pressure control in obese subjects with treated but inadequately controlled hypertension.
|
|
Academic Article
|
Quality of life measured in a practice-based hypertension trial of an angiotensin receptor blocker.
|
|
Academic Article
|
Rosiglitazone reduces urinary albumin excretion in type II diabetes.
|
|
Academic Article
|
What have we learned from the current trials?
|
|
Academic Article
|
The role of calcium antagonists in chronic kidney disease.
|
|
Academic Article
|
Control of blood pressure and other cardiovascular risk factors at different practice settings: outcomes of care provided to diabetic women compared to men.
|
|
Academic Article
|
The relationship between magnitude of proteinuria reduction and risk of end-stage renal disease: results of the African American study of kidney disease and hypertension.
|
|
Academic Article
|
Effects of drospirenone/17-beta estradiol on blood pressure and potassium balance in hypertensive postmenopausal women.
|
|
Academic Article
|
Are chlorthalidone and hydrochlorothiazide equivalent blood-pressure-lowering medications?
|
|
Academic Article
|
Treatment of microalbuminuria in hypertensive subjects with elevated cardiovascular risk: results of the IMPROVE trial.
|
|
Academic Article
|
Hypertension treatment guidelines: practical implications.
|
|
Academic Article
|
Are beta blockers passé for the treatment of hypertension?
|
|
Academic Article
|
Rationale and design of a study to evaluate management of proteinuria in patients at high risk for vascular events: the IMPROVE trial.
|
|
Academic Article
|
The efficacy and safety of low- and high-dose fixed combinations of irbesartan/hydrochlorothiazide in patients with uncontrolled systolic blood pressure on monotherapy: the INCLUSIVE trial.
|
|
Academic Article
|
Efficacy and safety of coadministered amlodipine and atorvastatin in patients with hypertension and dyslipidemia: results of the AVALON trial.
|
|
Academic Article
|
beta-blocker use and diabetes symptom score: results from the GEMINI study.
|
|
Academic Article
|
Controlled-release carvedilol in the treatment of essential hypertension.
|
|
Academic Article
|
Combination therapy with Renin-Angiotensin-aldosterone receptor blockers for hypertension: how far have we come?
|
|
Academic Article
|
Should beta-blockers be used to control hypertension in people with chronic kidney disease?
|
|
Academic Article
|
Efficacy and safety of fixed combinations of irbesartan/hydrochlorothiazide in older vs younger patients with hypertension uncontrolled with monotherapy.
|
|
Academic Article
|
The JNC 7 approach compared to conventional treatment in diabetic patients with hypertension: a double-blind trial of initial monotherapy vs. combination therapy.
|
|
Academic Article
|
State of hypertension management in the United States: confluence of risk factors and the prevalence of resistant hypertension.
|
|
Academic Article
|
Newer combination therapies in the management of hypertension: an update.
|
|
Academic Article
|
Blood pressure control and improved cardiovascular outcomes in the International Verapamil SR-Trandolapril Study.
|
|
Academic Article
|
Intervention at lower blood pressure levels to achieve target goals in type 2 diabetes: PRADID (PResión Arterial en DIabéticos tipo Dos) study.
|
|
Academic Article
|
Comparative efficacy of two different beta-blockers on 24-hour blood pressure control.
|
|
Academic Article
|
A selective endothelin-receptor antagonist to reduce blood pressure in patients with treatment-resistant hypertension: a randomised, double-blind, placebo-controlled trial.
|
|
Academic Article
|
Gender disparity in outcomes of care and management for diabetes and the metabolic syndrome.
|
|
Academic Article
|
Comparative antihypertensive efficacy of angiotensin receptor blocker-based treatment in African-American and white patients.
|
|
Academic Article
|
Efficacy of a once-daily formulation of carvedilol for the treatment of hypertension.
|
|
Academic Article
|
CYP3A4 and CYP3A5 polymorphisms and blood pressure response to amlodipine among African-American men and women with early hypertensive renal disease.
|
|
Academic Article
|
2010 ACCF/AHA/AATS/ACR/ASA/SCA/SCAI/SIR/STS/SVM Guidelines for the diagnosis and management of patients with thoracic aortic disease: Executive summary: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, American Association for Thoracic Surgery, American College of Radiology, American Stroke Association, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, Society of Interve...
|
|
Academic Article
|
Antihypertensive efficacy of Irbesartan/HCTZ in men and women with the metabolic syndrome and type 2 diabetes.
|
|
Academic Article
|
Divergent results using clinic and ambulatory blood pressures: report of a darusentan-resistant hypertension trial.
|
|
Academic Article
|
Editorial perspective. Should microalbuminuria ever be considered as a renal endpoint in any clinical trial?
|
|
Academic Article
|
2010 ACCF/AHA/AATS/ACR/ASA/SCA/SCAI/SIR/STS/SVM guidelines for the diagnosis and management of patients with thoracic aortic disease: executive summary. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, American Association for Thoracic Surgery, American College of Radiology, American Stroke Association, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, Society of Interve...
|
|
Academic Article
|
Amlodipine and valsartan combined and as monotherapy in stage 2, elderly, and black hypertensive patients: subgroup analyses of 2 randomized, placebo-controlled studies.
|
|
Academic Article
|
Effects of the angiotensin receptor blocker azilsartan medoxomil versus olmesartan and valsartan on ambulatory and clinic blood pressure in patients with stages 1 and 2 hypertension.
|
|
Academic Article
|
Effect of combining extended-release carvedilol and lisinopril in hypertension: results of the COSMOS study.
|
|
Academic Article
|
Should all patients with type 2 diabetes receive initial combination therapy: an assessment of the ADVANCE trial.
|
|
Academic Article
|
Beta-blockers in the treatment of hypertension: new data, new directions.
|
|
Academic Article
|
Limitations of metformin use in patients with kidney disease: are they warranted?
|
|
Academic Article
|
Comparison of the novel angiotensin II receptor blocker azilsartan medoxomil vs valsartan by ambulatory blood pressure monitoring.
|
|
Academic Article
|
Dual therapy in hypertensive patients with coronary artery disease: the role of calcium channel blockers and beta-blockers.
|
|
Academic Article
|
Catheter-based renal denervation for resistant hypertension: rationale and design of the SYMPLICITY HTN-3 Trial.
|
|
Academic Article
|
EXamination of cArdiovascular outcoMes with alogliptIN versus standard of carE in patients with type 2 diabetes mellitus and acute coronary syndrome (EXAMINE): a cardiovascular safety study of the dipeptidyl peptidase 4 inhibitor alogliptin in patients with type 2 diabetes with acute coronary syndrome.
|
|
Academic Article
|
Baroreflex activation therapy provides durable benefit in patients with resistant hypertension: results of long-term follow-up in the Rheos Pivotal Trial.
|
|
Academic Article
|
Single-pill combination of telmisartan/amlodipine versus amlodipine monotherapy in diabetic hypertensive patients: an 8-week randomized, parallel-group, double-blind trial.
|
|
Academic Article
|
Mineralocorticoid receptor antagonists for heart failure with reduced ejection fraction: integrating evidence into clinical practice.
|
|
Academic Article
|
The diabetes subgroup baseline characteristics of the Avoiding Cardiovascular Events Through Combination Therapy in Patients Living With Systolic Hypertension (ACCOMPLISH) trial.
|
|
Academic Article
|
Are renin-angiotensin-aldosterone system blockers distinguishable based on cardiovascular and renal outcomes in nephropathy?
|
|
Academic Article
|
Hypertension goals in advanced-stage kidney disease.
|
|
Academic Article
|
Tight blood pressure control and cardiovascular outcomes among hypertensive patients with diabetes and coronary artery disease.
|
|
Academic Article
|
Blood pressure-lowering efficacy of the fixed-dose combination of azilsartan medoxomil and chlorthalidone: a factorial study.
|
|
Academic Article
|
Telmisartan in incipient and overt diabetic renal disease.
|
|
Academic Article
|
Approaches for targeting blood pressure control in sleep disorders.
|
|
Academic Article
|
Differential effect of beta-blocker therapy on insulin resistance as a function of insulin sensitizer use: results from GEMINI.
|
|
Academic Article
|
Beta-blocker therapy in hypertension: a need to pause and reflect.
|
|
Academic Article
|
Effects of different ACE inhibitor combinations on albuminuria: results of the GUARD study.
|
|
Academic Article
|
Demographic analyses of the effects of carvedilol vs metoprolol on glycemic control and insulin sensitivity in patients with type 2 diabetes and hypertension in the Glycemic Effects in Diabetes Mellitus: Carvedilol-Metoprolol Comparison in Hypertensives (GEMINI) study.
|
|
Academic Article
|
Risk of hyperkalemia in nondiabetic patients with chronic kidney disease receiving antihypertensive therapy.
|
|
Academic Article
|
Newer renin-angiotensin-aldosterone system blocker combinations: is there an advantage?
|
|
Academic Article
|
Renal outcomes in hypertensive Black patients at high cardiovascular risk.
|
|
Academic Article
|
Antihypertensive treatment with and without benazepril in patients with chronic renal insufficiency: a US economic evaluation.
|
|
Academic Article
|
A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial.
|
|
Academic Article
|
Amlodipine/benazepril combination therapy for hypertensive patients nonresponsive to benazepril monotherapy.
|
|
Academic Article
|
Clinical outcomes in the diabetes cohort of the INternational VErapamil SR-Trandolapril study.
|
|
Academic Article
|
Atlas vertebra realignment and achievement of arterial pressure goal in hypertensive patients: a pilot study.
|
|
Academic Article
|
Predictors of blood pressure response to intensified and fixed combination treatment of hypertension: the ACCOMPLISH study.
|
|
Academic Article
|
Serum potassium and clinical outcomes in the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS).
|
|
Academic Article
|
Efficacy and duration of benazepril plus amlodipine or hydrochlorothiazide on 24-hour ambulatory systolic blood pressure control.
|
|
Academic Article
|
The comparative effects of azilsartan medoxomil and olmesartan on ambulatory and clinic blood pressure.
|
|
Academic Article
|
Effects of naproxcinod on blood pressure in patients with osteoarthritis.
|
|
Academic Article
|
Renin-angiotensin inhibition in systolic heart failure and chronic kidney disease.
|
|
Academic Article
|
Azilsartan medoxomil plus chlorthalidone reduces blood pressure more effectively than olmesartan plus hydrochlorothiazide in stage 2 systolic hypertension.
|
|
Academic Article
|
Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease.
|
|
Academic Article
|
Association of BP variability with mortality among African Americans with CKD.
|
|
Academic Article
|
A trial of 2 strategies to reduce nocturnal blood pressure in blacks with chronic kidney disease.
|
|
Academic Article
|
Rationale and trial design of Bardoxolone Methyl Evaluation in Patients with Chronic Kidney Disease and Type 2 Diabetes: the Occurrence of Renal Events (BEACON).
|
|
Academic Article
|
Effects of nebivolol on aortic compliance in patients with diabetes and maximal renin angiotensin system blockade: the EFFORT study.
|
|
Academic Article
|
Interventional cardiology: Indications for renal denervation: a balanced approach?
|
|
Academic Article
|
Noninsulin glucose-lowering agents for the treatment of patients on dialysis.
|
|
Academic Article
|
Resistant hypertension: a frequent and ominous finding among hypertensive patients with atherothrombosis.
|
|
Academic Article
|
Systolic blood pressure and cardiovascular outcomes during treatment of hypertension.
|
|
Academic Article
|
Efficacy of baroreflex activation therapy for the treatment of resistant hypertension.
|
|
Academic Article
|
Randomized study of antihypertensive efficacy and safety of combination aliskiren/valsartan vs valsartan monotherapy in hypertensive participants with type 2 diabetes mellitus.
|
|
Academic Article
|
Risk factors for heart failure in patients with type 2 diabetes mellitus and stage 4 chronic kidney disease treated with bardoxolone methyl.
|
|
Academic Article
|
Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes mellitus and chronic kidney disease.
|
|
Academic Article
|
Efficacy and safety of canagliflozin in patients with type 2 diabetes and stage 3 nephropathy.
|
|
Academic Article
|
Clinical practice guidelines for the management of hypertension in the community: a statement by the American Society of Hypertension and the International Society of Hypertension.
|
|
Academic Article
|
Predictors and outcomes of resistant hypertension among patients with coronary artery disease and hypertension.
|
|
Academic Article
|
Lowering blood pressure limits in patients with type 2 diabetes: is it still warranted?
|
|
Academic Article
|
Predictors of blood pressure response in the SYMPLICITY HTN-3 trial.
|
|
Academic Article
|
Renal denervation for resistant hypertension and beyond.
|
|
Academic Article
|
12-month blood pressure results of catheter-based renal artery denervation for resistant hypertension: the SYMPLICITY HTN-3 trial.
|
|
Academic Article
|
Renal Denervation After SYMPLICITY HTN-3: Where Do We Go?
|
|
Academic Article
|
Summary and Conclusions.
|
|
Academic Article
|
New potassium binders for the treatment of hyperkalemia: current data and opportunities for the future.
|
|
Academic Article
|
An analysis of the blood pressure and safety outcomes to renal denervation in African Americans and Non-African Americans in the SYMPLICITY HTN-3 trial.
|
|
Academic Article
|
The double challenge of resistant hypertension and chronic kidney disease.
|
|
Academic Article
|
Correlations of plasma renin activity and aldosterone concentration with ambulatory blood pressure responses to nebivolol and valsartan, alone and in combination, in hypertension.
|
|
Academic Article
|
Effects of aliskiren in diabetic and non-diabetic patients with coronary artery disease: Insights from AQUARIUS.
|
|
Academic Article
|
Cardiovascular Outcomes According to Systolic Blood Pressure in Patients With and Without Diabetes: An ACCOMPLISH Substudy.
|
|
Academic Article
|
Angiotensin-Converting Enzyme Inhibitor Use and Major Cardiovascular Outcomes in Type 2 Diabetes Mellitus Treated With the Dipeptidyl Peptidase 4 Inhibitor Alogliptin.
|
|
Academic Article
|
Current Status of Renal Denervation in Hypertension.
|
|
Academic Article
|
Effect of Sitagliptin on Kidney Function and Respective Cardiovascular Outcomes in Type 2 Diabetes: Outcomes From TECOS.
|
|
Academic Article
|
Catheter-Based Renal Denervation for Resistant Hypertension: Will It Ever Be Ready for "Prime Time"?
|
|
Academic Article
|
Impact of eplerenone on cardiovascular outcomes in heart failure patients with hypokalaemia.
|
|
Academic Article
|
An exploratory propensity score matched comparison of second-generation and first-generation baroreflex activation therapy systems.
|
|
Academic Article
|
Serial Measurement of High-Sensitivity Troponin I and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus in the EXAMINE Trial (Examination of Cardiovascular Outcomes With Alogliptin Versus Standard of Care).
|
|
Academic Article
|
Sustained Reduction of Blood Pressure With Baroreceptor Activation Therapy: Results of the 6-Year Open Follow-Up.
|
|
Academic Article
|
Evaluation of the angiotensin II receptor blocker azilsartan medoxomil in African-American patients with hypertension.
|
|
Academic Article
|
Severe menses-associated hypertension successfully treated with gonadotropin-releasing hormone agonist.
|
|
Academic Article
|
Prior Medications and the Cardiovascular Benefits From Combination Angiotensin-Converting Enzyme Inhibition Plus Calcium Channel Blockade Among High-Risk Hypertensive Patients.
|
|
Academic Article
|
High-sensitivity C-reactive protein, low-density lipoprotein cholesterol and cardiovascular outcomes in patients with type 2 diabetes in the EXAMINE (Examination of Cardiovascular Outcomes with Alogliptin versus Standard of Care) trial.
|
|
Academic Article
|
Prevalent and Incident Heart Failure in Cardiovascular Outcome Trials of Patients With Type 2 Diabetes.
|
|
Academic Article
|
Early and Chronic Dipeptidyl-Peptidase-IV Inhibition and Cardiovascular Events in Patients With Type 2 Diabetes Mellitus After an Acute Coronary Syndrome: A Landmark Analysis of the EXAMINE Trial.
|
|
Academic Article
|
Bardoxolone Methyl Improves Kidney Function in Patients with Chronic Kidney Disease Stage 4 and Type 2 Diabetes: Post-Hoc Analyses from Bardoxolone Methyl Evaluation in Patients with Chronic Kidney Disease and Type 2 Diabetes Study.
|
|
Academic Article
|
Olmesartan-based monotherapy vs combination therapy in hypertension: A meta-analysis based on age and chronic kidney disease status.
|
|
Academic Article
|
Long-term efficacy and tolerability of azilsartan medoxomil/chlorthalidone vs olmesartan medoxomil/hydrochlorothiazide in chronic kidney disease.
|
|
Academic Article
|
High screen failure rate in patients with resistant hypertension: Findings from SYMPLICITY HTN-3.
|
|
Academic Article
|
Cardiovascular and Renal Outcomes With Canagliflozin According to Baseline Kidney Function.
|
|
Academic Article
|
Long-term effects of patiromer for hyperkalaemia treatment in patients with mild heart failure and diabetic nephropathy on angiotensin-converting enzymes/angiotensin receptor blockers: results from AMETHYST-DN.
|
|
Academic Article
|
MY APPROACH to the elderly patient with resistant hypertension.
|
|
Academic Article
|
Similarities and Differences Between the ACC/AHA and ESH/ESC Guidelines for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults.
|
|
Academic Article
|
Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial.
|
|
Academic Article
|
Major Advancements in Slowing Diabetic Kidney Disease Progression: Focus on SGLT2 Inhibitors.
|
|
Academic Article
|
Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups.
|
|
Academic Article
|
Design and Baseline Characteristics of the Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease Trial.
|
|
Academic Article
|
Design and Baseline Characteristics of the Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease Trial.
|
|
Academic Article
|
Microvascular and Cardiovascular Outcomes According to Renal Function in Patients Treated With Once-Weekly Exenatide: Insights From the EXSCEL Trial.
|
|
Academic Article
|
Improved Sleep Quality Improves Blood Pressure Control among Patients with Chronic Kidney Disease: A Pilot Study.
|
|
Academic Article
|
Renal, Cardiovascular, and Safety Outcomes of Canagliflozin by Baseline Kidney Function: A Secondary Analysis of the CREDENCE Randomized Trial.
|
|
Academic Article
|
Effects of canagliflozin on anaemia in patients with type 2 diabetes and chronic kidney disease: a post-hoc analysis from the CREDENCE trial.
|
|
Academic Article
|
Effects of Canagliflozin in Patients with Baseline eGFR <30 ml/min per 1.73 m2: Subgroup Analysis of the Randomized CREDENCE Trial.
|
|
Academic Article
|
Cardiovascular Benefits of Angiotensin-Converting Enzyme Inhibition Plus Calcium Channel Blockade in Patients Achieving Tight Blood Pressure Control and With Resistant Hypertension.
|
|
Academic Article
|
Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes.
|
|
Academic Article
|
Individual Atrasentan Exposure is Associated With Long-term Kidney and Heart Failure Outcomes in Patients With Type 2 Diabetes and Chronic Kidney Disease.
|
|
Academic Article
|
Renal denervation in hypertension patients: Proceedings from an expert consensus roundtable cosponsored by SCAI and NKF.
|
|
Academic Article
|
Body weight changes in patients with type 2 diabetes and a recent acute coronary syndrome: an analysis from the EXAMINE trial.
|
|
Academic Article
|
Early Response in Albuminuria and Long-Term Kidney Protection during Treatment with an Endothelin Receptor Antagonist: A Prespecified Analysis from the SONAR Trial.
|
|
Academic Article
|
Novel Renal Autologous Cell Therapy for Type 2 Diabetes Mellitus Chronic Diabetic Kidney Disease: Clinical Trial Design.
|
|
Academic Article
|
Treatment of Resistant Hypertension With Endovascular Baroreflex Amplification: 3-Year Results From the CALM-FIM Study.
|
|
Academic Article
|
Long-term outcomes after catheter-based renal artery denervation for resistant hypertension: final follow-up of the randomised SYMPLICITY HTN-3 Trial.
|
|
Academic Article
|
Dual endothelin antagonist aprocitentan for resistant hypertension (PRECISION): a multicentre, blinded, randomised, parallel-group, phase 3 trial.
|
|
Academic Article
|
Finerenone and Heart Failure Outcomes by Kidney Function/Albuminuria in Chronic Kidney Disease and Diabetes.
|
|
Academic Article
|
Kidney and Cardiovascular Effects of Canagliflozin According to Age and Sex: A Post Hoc Analysis of the CREDENCE Randomized Clinical Trial.
|